Long-term effectiveness and safety of annual biosimilar Rituximab retreatment in seropositive Rheumatoid Arthritis: A 4-year real-world study.
Rituximab is an established biologic disease-modifying antirheumatic drug (bDMARD) for rheumatoid arthritis (RA) patients with inadequate response to conventional synthetic DMARDs, particularly in seropositive disease. In resource-limited settings such as India, biosimilar ritux…